Assist Prof Dr. DEROSA LISA – IMMUNOLOGY ONCOLOGY – Best Researcher Award 


Author Profile 

Early Academic Pursuits 🎓

She, MD, PhD, began her academic journey with a deep passion for medicine and oncology. She completed her MD at Pisa University in 2008, followed by a qualifying examination and registration as a physician in Italy in 2009. He pursued a specialty in medical oncology at Pisa University, achieving board certification in 2014. Her dedication to advancing her knowledge led her to complete an M2 in Pharmacology, Clinical Trial in Oncology at Pisa University in 2015. She further enhanced her expertise with a European University Diploma in Translational and Clinical Research in Oncology (DUERTECC) from Paris-Sud University in 2016, and a University Diploma in Animal Experimentation from Sorbonne University in 2018.

In 2019, he earned her PhD in Immunology from Paris-Sud University. Her academic excellence was further recognized when she became an Associate Professor of Immunology at Paris-Saclay University in 2023.

 Professional Endeavors 💼

Her professional career is marked by her commitment to cancer research and patient care. She holds several key positions at the prestigious Gustave Roussy Cancer Center (GRCC) in Villejuif-Grand Paris, France. As the Clinical Director of the ClinicObiome Cancer Immunology Department, she oversees groundbreaking programs focused on the interplay between the gut microbiome and cancer immunotherapy. She also serves as a Senior Specialist in Medical Oncology and a Research Associate in the U1015 Cancer Immunology Department at GRCC.

In addition to her roles at GRCC, she is an Associate Professor of Immunology at the Medical School of Paris-Saclay University. Her specialty lies in tumor immunology and cancer immunotherapy, where she has made significant contributions since 2016.

Contributions and Research Focus on IMMUNOLOGY ONCOLOGY📚

Her research focuses on the immunosuppressive effects of antibiotics in cancer immunotherapy and the role of gut microbiota in regulating antitumor immunity. She has pioneered several concepts in this field, demonstrating how gut microbiota composition can influence the efficacy of immune checkpoint inhibitors. Her work has been widely published, with over 100 papers indexed on PubMed, including multiple contributions to high-impact journals such as Nature Medicine, Cell, and Cancer Discovery. Her impressive H-factor of 38 and 8,515 citations underscore her influence and the importance of her research in the scientific community.

Accolades and Recognition 🏆

Throughout her career, she has received numerous prestigious awards and honors, highlighting her contributions to oncology and immunology. Notable awards include multiple Merit Awards from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). In 2023, she received the Conquer Cancer Foundation ASCO Merit Award. Other significant recognitions include the Best Scientific Paper Award from European Urology in 2021 and the EATI Award in 2020.

 Impact and Influence 🌍

Her work has had a profound impact on the field of cancer immunotherapy. Her research on the gut microbiome’s role in cancer treatment has opened new avenues for understanding and enhancing the efficacy of immunotherapy. She leads the Microbiota-centered intervention program (ClinicObiome) at GRCC and co-directs significant clinical programs such as the RHU Clinical Program Grant “Immunolife” and the EU Program Grant “Oncobiome”. These programs aim to develop innovative strategies for cancer treatment based on her groundbreaking research.

 Legacy and Future Contributions 🔮

Her legacy in the field of oncology and immunology is marked by her pioneering research and significant contributions to cancer treatment. Her ongoing work continues to push the boundaries of medical science, offering new hope for cancer patients worldwide. As she advances in her career, she is poised to make even greater strides in understanding and leveraging the immune system’s role in cancer therapy. Her dedication to research, patient care, and education ensures that her impact will be felt for generations to come.

Notable Publications 

  1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
  2. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
  3. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19
  4. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials
  5. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
  6. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
  7. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
  8. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
  9. Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

You May Also Like